Research Topic

Current Innovations in GI-Oncology: Where do we stand?

About this Research Topic

In GI-Oncology, the progress of sophisticated treatment options like TKI or immunotherapy lags behind other malignant diseases like lung cancer, breast cancer or hematological diseases. Currently, there are interesting new data on tumor biology and “intelligent” treatment options. For example, there are new data on PARP-Inhibition in pancreatic cancer, BRAF inhibition in CRC, NTRK-targeting in patients, a wave of data on mutations in metastatic cholangiocellular carcinoma, immunotherapy for colorectal cancer and MSI tumors in general. Several new concepts like CMS are emerging and will possibly find its way into clinical routine within the next years. This progress, however, is derived either from complex data (f.e. CMS) or is limited to defined, small subgroups of patients, which makes the classification of these data, especially for clinical use, challenging.

Aim of this research topic is to describe the current hot-topics in GI-oncology and which value they have for (i) clinical use now and in the near future, (ii) understanding of disease biology and (iii) what we can expect from these for the future. Suggested topics, include, but not limited to the following:

• Immunotherapy in GI-Cancers: especially the link between molecular genetics and immunooncology
• Targeted treatment concepts: ranging from classical EGFR-inhibiton over new BRAF inhibition to newer FGFR-2-inhibition
• Molecular oncology: the role of molecular profiling in GI-oncology – are GI-cancers or subgroups (f.e. MSI) a more promising entity for this approach as other tumors?
• MSI: molecular basis and the link to immunosensitivity, is there an understanding of non immuno-responsive MSI tumors
• CMS: where do we stand and where do we go?
• BRCA/BRCAness in GI-cancers: ready for clinical use? Different from other “new mutations”, BRCAness is less defined but promising. Focus should be on BRCAness
• Targeted treatment concepts for known mutations: BRAF, NTRK, IDH1, FGFR2, BRCA ….
• Molecular profiling in GI-cancer: describing efficacy (CARIS, other platforms…) and compare to other entities (original article)


Keywords: immunotherapy, targeted treatments, molecular profiling, MSI, gastrointestinal oncology


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

In GI-Oncology, the progress of sophisticated treatment options like TKI or immunotherapy lags behind other malignant diseases like lung cancer, breast cancer or hematological diseases. Currently, there are interesting new data on tumor biology and “intelligent” treatment options. For example, there are new data on PARP-Inhibition in pancreatic cancer, BRAF inhibition in CRC, NTRK-targeting in patients, a wave of data on mutations in metastatic cholangiocellular carcinoma, immunotherapy for colorectal cancer and MSI tumors in general. Several new concepts like CMS are emerging and will possibly find its way into clinical routine within the next years. This progress, however, is derived either from complex data (f.e. CMS) or is limited to defined, small subgroups of patients, which makes the classification of these data, especially for clinical use, challenging.

Aim of this research topic is to describe the current hot-topics in GI-oncology and which value they have for (i) clinical use now and in the near future, (ii) understanding of disease biology and (iii) what we can expect from these for the future. Suggested topics, include, but not limited to the following:

• Immunotherapy in GI-Cancers: especially the link between molecular genetics and immunooncology
• Targeted treatment concepts: ranging from classical EGFR-inhibiton over new BRAF inhibition to newer FGFR-2-inhibition
• Molecular oncology: the role of molecular profiling in GI-oncology – are GI-cancers or subgroups (f.e. MSI) a more promising entity for this approach as other tumors?
• MSI: molecular basis and the link to immunosensitivity, is there an understanding of non immuno-responsive MSI tumors
• CMS: where do we stand and where do we go?
• BRCA/BRCAness in GI-cancers: ready for clinical use? Different from other “new mutations”, BRCAness is less defined but promising. Focus should be on BRCAness
• Targeted treatment concepts for known mutations: BRAF, NTRK, IDH1, FGFR2, BRCA ….
• Molecular profiling in GI-cancer: describing efficacy (CARIS, other platforms…) and compare to other entities (original article)


Keywords: immunotherapy, targeted treatments, molecular profiling, MSI, gastrointestinal oncology


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

22 December 2020 Abstract
21 April 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

22 December 2020 Abstract
21 April 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..